Co-Authors
This is a "connection" page, showing publications co-authored by GORDON B MILLS and DAVID SANGHYUN HONG.
Connection Strength
0.495
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.135
-
A decision support framework for genomically informed investigational cancer therapy. J Natl Cancer Inst. 2015 Jul; 107(7).
Score: 0.134
-
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. Breast Cancer Res. 2019 07 05; 21(1):78.
Score: 0.045
-
Clinical Use of Precision Oncology Decision Support. JCO Precis Oncol. 2017; 2017.
Score: 0.040
-
Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. Clin Cancer Res. 2017 Sep 15; 23(18):5648-5656.
Score: 0.039
-
BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. Mol Cancer Ther. 2016 06; 15(6):1397-404.
Score: 0.036
-
Clinical next generation sequencing to identify actionable aberrations in a phase I program. Oncotarget. 2015 Aug 21; 6(24):20099-110.
Score: 0.034
-
Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications. PLoS One. 2014; 9(12):e115383.
Score: 0.033